EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENTExclusive Licensing and Distribution Agreement • June 9th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This Exclusive Licensing and Distribution Agreement (“Agreement”) is entered into and effective as of June 03, 2016 (“Effective Date”), by and between FluoroPharma Medical, Inc., a company organized and existing under the laws of Nevada, with its principal place of business located at 8 Hillside Avenue, Suite 207, Montclair, New Jersey, U.S., (“FluoroPharma”) and Sinotau USA, Inc. (a subsidiary of Sinotau Pharmaceutical Group, Chinese Name: 北京先通国际医药科技股份有限公司, i.e. Beijing Xiantong Guoji Yiyao Keji Gufen Youxian Gongsi a company organized and existing under the laws of the People’s Republic of China with registered address at Room 6168, #1 Building, #2 Courtyard, Heng Fu Middle Street, Science City, Fengtai District, Beijing China) a company organized under the laws of Delaware, with its principal place of business located at 27 Drydock Avenue, STE 7, Boston, Massachusetts, U.S. (“Sinotau”). FluoroPharma and Sinotau are each referred to herein by name or as a “Party” or, collectively, as
FluoroPharma Enters Development and Commercialization Agreement for China and CanadaCommercialization Agreement • June 9th, 2016 • Fluoropharma Medical, Inc. • In vitro & in vivo diagnostic substances
FluoroPharma Medical Inc. (OTCQB: FPMI) has entered an exclusive agreement with Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceutical Group, a pharmaceutical enterprise with a focus on critical therapeutic areas. With this agreement, Sinotau will develop and commercialize FluoroPharma’s proprietary cardiac imaging assets CardioPET and BFPET in China and Canada. These agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging.
